1-20 of 29
Antoni Ribas
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Expression of Concern: Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity

Free
Aayoung Hong, Marco Piva, Sixue Liu, Willy Hugo, Shirley H. Lomeli, Vincent Zoete, Christopher E. Randolph, Zhentao Yang, Yan Wang, Jordan J. Lee, Skylar J. Lo, Lu Sun, Agustin Vega-Crespo, Alejandro J. Garcia, David B. Shackelford, Steven M. Dubinett, Philip O. Scumpia, Stephanie D. Byrum, Alan J. Tackett, Timothy R. Donahue, Olivier Michielin, Sheri L. Holmen, Antoni Ribas, Gatien Moriceau, Roger S. Lo
Journal: Cancer Discovery
Cancer Discov (2024) 14 (7): 1357.
https://doi.org/10.1158/2159-8290.CD-24-0613
Published: 01 July 2024
View article titled, Expression of Concern: Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
Open the PDF for Expression of Concern: Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity in another window
Journal Articles

Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma

Open Access
Prashanthi Dharanipragada, Xiao Zhang, Sixue Liu, Shirley H. Lomeli, Aayoung Hong, Yan Wang, Zhentao Yang, Kara Z. Lo, Agustin Vega-Crespo, Antoni Ribas, Stergios J. Moschos, Gatien Moriceau, Roger S. Lo
Journal: Cancer Discovery
Cancer Discov (2023) 13 (4): 880–909.
https://doi.org/10.1158/2159-8290.CD-22-0787
Published: 03 April 2023
View article titled, Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma
Open the PDF for Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma in another window
Includes: Supplementary data
Journal Articles

CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Free
Sarah M. Larson, Christopher M. Walthers, Brenda Ji, Sanaz N. Ghafouri, Jacob Naparstek, Jacqueline Trent, Jia Ming Chen, Mobina Roshandell, Caitlin Harris, Mobina Khericha, Thomas Schweppe, Beata Berent-Maoz, Stanley B. Gosliner, Amr Almaktari, Melanie Ayala Ceja, Martin S. Allen-Auerbach, Jonathan Said, Karla Nawaly, Monica Mead, Sven de Vos, Patricia A. Young, Caspian Oliai, Gary J. Schiller, John M. Timmerman, Antoni Ribas, Yvonne Y. Chen
Journal: Cancer Discovery
Cancer Discov (2023) 13 (3): 580–597.
https://doi.org/10.1158/2159-8290.CD-22-0964
Published: 01 March 2023
View article titled, CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Open the PDF for CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma in another window
Includes: Supplementary data
Journal Articles

When Cancer Cells Become the Enablers of an Antitumor Immune Response

Available to Purchase
Antoni Ribas, W. Nicholas Haining, Ton N.M. Schumacher
Journal: Cancer Discovery
Cancer Discov (2022) 12 (10): 2244–2248.
https://doi.org/10.1158/2159-8290.CD-22-0706
Published: 05 October 2022
View article titled, When Cancer Cells Become the Enablers of an Antitumor Immune Response
Open the PDF for When Cancer Cells Become the Enablers of an Antitumor Immune Response in another window
Journal Articles

Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma

Available to Purchase
Kenneth F. Grossmann, Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp, Teresa M. Petrella, Thach-Giao Truong, Nikhil I. Khushalani, Justine V. Cohen, Elizabeth I. Buchbinder, Kari Kendra, Pauline Funchain, Karl D. Lewis, Robert M. Conry, Bartosz Chmielowski, Ragini R. Kudchadkar, Douglas B. Johnson, Hongli Li, James Moon, Zeynep Eroglu, Brian Gastman, Magdalena Kovacsovics-Bankowski, Krishna S. Gunturu, Scot W. Ebbinghaus, Sama Ahsan, Nageatte Ibrahim, Elad Sharon, Larissa A. Korde, John M. Kirkwood, Antoni Ribas
Journal: Cancer Discovery
Cancer Discov (2022) 12 (3): 644–653.
https://doi.org/10.1158/2159-8290.CD-21-1141
Published: 08 March 2022
View article titled, Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma
Open the PDF for Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma in another window
Includes: Supplementary data
Journal Articles

Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma

Open Access
Antoni Ribas, Theresa Medina, John M. Kirkwood, Yousef Zakharia, Rene Gonzalez, Diwakar Davar, Bartosz Chmielowski, Katie M. Campbell, Riyue Bao, Heather Kelley, Aaron Morris, David Mauro, James E. Wooldridge, Jason J. Luke, George J. Weiner, Arthur M. Krieg, Mohammed M. Milhem
Journal: Cancer Discovery
Cancer Discov (2021) 11 (12): 2998–3007.
https://doi.org/10.1158/2159-8290.CD-21-0425
Published: 01 December 2021
View article titled, Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma
Open the PDF for Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity

Free
Darya Alizadeh, Robyn A. Wong, Sharareh Gholamin, Madeleine Maker, Maryam Aftabizadeh, Xin Yang, Joseph R. Pecoraro, John D. Jeppson, Dongrui Wang, Brenda Aguilar, Renate Starr, Claire B. Larmonier, Nicolas Larmonier, Min-Hsuan Chen, Xiwei Wu, Antoni Ribas, Behnam Badie, Stephen J. Forman, Christine E. Brown
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2021) 11 (9): 2248–2265.
https://doi.org/10.1158/2159-8290.CD-20-1661
Published: 01 September 2021
View article titled, IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity
Open the PDF for IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity in another window
Includes: Supplementary data
Journal Articles

Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy

Open Access
Mario E. Lacouture, Zev A. Wainberg, Anisha B. Patel, Milan J. Anadkat, Salomon M. Stemmer, Einat Shacham-Shmueli, Egmidio Medina, Galit Zelinger, Noa Shelach, Antoni Ribas
Journal: Cancer Discovery
Cancer Discov (2021) 11 (9): 2158–2167.
https://doi.org/10.1158/2159-8290.CD-20-1847
Published: 01 September 2021
View article titled, Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy
Open the PDF for Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy in another window
Includes: Supplementary data
Journal Articles

Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective

Free
Keith T. Flaherty, James H. Doroshow, Susan Galbraith, Antoni Ribas, Paul G. Kluetz, Richard Pazdur, Marc R. Theoret
Journal: Cancer Discovery
Cancer Discov (2021) 11 (8): 1881–1885.
https://doi.org/10.1158/2159-8290.CD-21-0850
Published: 01 August 2021
View article titled, Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective
Open the PDF for Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective in another window
Journal Articles

Repurposing of Anticancer Drugs Expands Possibilities for Antiviral and Anti-Inflammatory Discovery in COVID-19

Free
Mihaela Aldea, Jean-Marie Michot, Francois-Xavier Danlos, Antoni Ribas, Jean-Charles Soria
Journal: Cancer Discovery
Cancer Discov (2021) 11 (6): 1336–1344.
https://doi.org/10.1158/2159-8290.CD-21-0144
Published: 01 June 2021
View article titled, Repurposing of Anticancer Drugs Expands Possibilities for Antiviral and Anti-Inflammatory Discovery in COVID-19
Open the PDF for Repurposing of Anticancer Drugs Expands Possibilities for Antiviral and Anti-Inflammatory Discovery in COVID-19 in another window
Journal Articles

T Cells as the Future of Cancer Therapy

Available to Purchase
Antoni Ribas
Journal: Cancer Discovery
Cancer Discov (2021) 11 (4): 798–800.
https://doi.org/10.1158/2159-8290.CD-21-0022
Published: 01 April 2021
View article titled, T Cells as the Future of Cancer Therapy
Open the PDF for T Cells as the Future of Cancer Therapy in another window
Journal Articles

Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity

Free
Aayoung Hong, Marco Piva, Sixue Liu, Willy Hugo, Shirley H. Lomeli, Vincent Zoete, Christopher E. Randolph, Zhentao Yang, Yan Wang, Jordan J. Lee, Skylar J. Lo, Lu Sun, Agustin Vega-Crespo, Alejandro J. Garcia, David B. Shackelford, Steven M. Dubinett, Philip O. Scumpia, Stephanie D. Byrum, Alan J. Tackett, Timothy R. Donahue, Olivier Michielin, Sheri L. Holmen, Antoni Ribas, Gatien Moriceau, Roger S. Lo
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2021) 11 (3): 714–735.
https://doi.org/10.1158/2159-8290.CD-20-0873
Published: 02 March 2021
View article titled, Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity
Open the PDF for Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity in another window
Includes: Supplementary data
Journal Articles

Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited

Free
Antoni Ribas, Rajarshi Sengupta, Trevan Locke, Sayyed Kaleem Zaidi, Katie M. Campbell, John M. Carethers, Elizabeth M. Jaffee, E. John Wherry, Jean-Charles Soria, Gypsyamber D'Souza
Journal: Cancer Discovery
Cancer Discov (2021) 11 (2): 233–236.
https://doi.org/10.1158/2159-8290.CD-20-1817
Published: 02 February 2021
View article titled, Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited
Open the PDF for Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited in another window
Includes: Supplementary data
Journal Articles

Epigenetic Suppression of Transgenic T-cell Receptor Expression via Gamma-Retroviral Vector Methylation in Adoptive Cell Transfer Therapy

Available to Purchase
Theodore S. Nowicki, Colin Farrell, Marco Morselli, Liudmilla Rubbi, Katie M. Campbell, Mignonette H. Macabali, Beata Berent-Maoz, Begoña Comin-Anduix, Matteo Pellegrini, Antoni Ribas
Journal: Cancer Discovery
Cancer Discov (2020) 10 (11): 1645–1653.
https://doi.org/10.1158/2159-8290.CD-20-0300
Published: 02 November 2020
View article titled, Epigenetic Suppression of Transgenic T-cell Receptor Expression via Gamma-Retroviral Vector Methylation in Adoptive Cell Transfer Therapy
Open the PDF for Epigenetic Suppression of Transgenic T-cell Receptor Expression via Gamma-Retroviral Vector Methylation in Adoptive Cell Transfer Therapy in another window
Includes: Supplementary data
Journal Articles

Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade

Available to Purchase
Davis Y. Torrejon, Gabriel Abril-Rodriguez, Ameya S. Champhekar, Jennifer Tsoi, Katie M. Campbell, Anusha Kalbasi, Giulia Parisi, Jesse M. Zaretsky, Angel Garcia-Diaz, Cristina Puig-Saus, Gardenia Cheung-Lau, Thomas Wohlwender, Paige Krystofinski, Agustin Vega-Crespo, Christopher M. Lee, Pau Mascaro, Catherine S. Grasso, Beata Berent-Maoz, Begoña Comin-Anduix, Siwen Hu-Lieskovan, Antoni Ribas
Journal: Cancer Discovery
Cancer Discov (2020) 10 (8): 1140–1157.
https://doi.org/10.1158/2159-8290.CD-19-1409
Published: 03 August 2020
View article titled, Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade
Open the PDF for Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade in another window
Includes: Supplementary data
Journal Articles

Trying for a BRAF Slam Dunk

Available to Purchase
Antoni Ribas, Roger S. Lo
Journal: Cancer Discovery
Cancer Discov (2020) 10 (5): 640–642.
https://doi.org/10.1158/2159-8290.CD-20-0231
Published: 01 May 2020
View article titled, Trying for a BRAF Slam Dunk
Open the PDF for Trying for a BRAF Slam Dunk in another window
Journal Articles

SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study

Free
Antoni Ribas, Theresa Medina, Shivaani Kummar, Asim Amin, Anusha Kalbasi, Joseph J. Drabick, Minal Barve, Gregory A. Daniels, Deborah J. Wong, Emmett V. Schmidt, Albert F. Candia, Robert L. Coffman, Abraham C.F. Leung, Robert S. Janssen
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2018) 8 (10): 1250–1257.
https://doi.org/10.1158/2159-8290.CD-18-0280
Published: 02 October 2018
View article titled, SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study
Open the PDF for SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study in another window
Includes: Supplementary data
Journal Articles

Immunotherapy Resistance by Inflammation-Induced Dedifferentiation

Free
Arnav Mehta, Yeon Joo Kim, Lidia Robert, Jennifer Tsoi, Begoña Comin-Anduix, Beata Berent-Maoz, Alistair J. Cochran, James S. Economou, Paul C. Tumeh, Cristina Puig-Saus, Antoni Ribas
Journal: Cancer Discovery
Cancer Discov (2018) 8 (8): 935–943.
https://doi.org/10.1158/2159-8290.CD-17-1178
Published: 02 August 2018
View article titled, Immunotherapy Resistance by Inflammation-Induced Dedifferentiation
Open the PDF for Immunotherapy Resistance by Inflammation-Induced Dedifferentiation in another window
Includes: Supplementary data
Journal Articles

Genetic Mechanisms of Immune Evasion in Colorectal Cancer

Free
Catherine S. Grasso, Marios Giannakis, Daniel K. Wells, Tsuyoshi Hamada, Xinmeng Jasmine Mu, Michael Quist, Jonathan A. Nowak, Reiko Nishihara, Zhi Rong Qian, Kentaro Inamura, Teppei Morikawa, Katsuhiko Nosho, Gabriel Abril-Rodriguez, Charles Connolly, Helena Escuin-Ordinas, Milan S. Geybels, William M. Grady, Li Hsu, Siwen Hu-Lieskovan, Jeroen R. Huyghe, Yeon Joo Kim, Paige Krystofinski, Mark D.M. Leiserson, Dennis J. Montoya, Brian B. Nadel, Matteo Pellegrini, Colin C. Pritchard, Cristina Puig-Saus, Elleanor H. Quist, Ben J. Raphael, Stephen J. Salipante, Daniel Sanghoon Shin, Eve Shinbrot, Brian Shirts, Sachet Shukla, Janet L. Stanford, Wei Sun, Jennifer Tsoi, Alexander Upfill-Brown, David A. Wheeler, Catherine J. Wu, Ming Yu, Syed H. Zaidi, Jesse M. Zaretsky, Stacey B. Gabriel, Eric S. Lander, Levi A. Garraway, Thomas J. Hudson, Charles S. Fuchs, Antoni Ribas, Shuji Ogino, Ulrike Peters
Journal: Cancer Discovery
Cancer Discov (2018) 8 (6): 730–749.
https://doi.org/10.1158/2159-8290.CD-17-1327
Published: 31 May 2018
View article titled, Genetic Mechanisms of Immune Evasion in Colorectal Cancer
Open the PDF for Genetic Mechanisms of Immune Evasion in Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

Free
Ryan J. Sullivan, Jeffrey R. Infante, Filip Janku, Deborah Jean Lee Wong, Jeffrey A. Sosman, Vicki Keedy, Manish R. Patel, Geoffrey I. Shapiro, James W. Mier, Anthony W. Tolcher, Andrea Wang-Gillam, Mario Sznol, Keith Flaherty, Elizabeth Buchbinder, Richard D. Carvajal, Anna M. Varghese, Mario E. Lacouture, Antoni Ribas, Sapna P. Patel, Gary A. DeCrescenzo, Caroline M. Emery, Anna L. Groover, Saurabh Saha, Mary Varterasian, Dean J. Welsch, David M. Hyman, Bob T. Li
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2018) 8 (2): 184–195.
https://doi.org/10.1158/2159-8290.CD-17-1119
Published: 04 February 2018
View article titled, First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
Open the PDF for First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study in another window
Includes: Supplementary data